Q1 2024 EPS Estimates for Tarsus Pharmaceuticals, Inc. Boosted by Analyst (NASDAQ:TARS)

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Research analysts at William Blair lifted their Q1 2024 earnings per share estimates for Tarsus Pharmaceuticals in a report released on Wednesday, April 17th. William Blair analyst T. Lugo now expects that the company will post earnings of ($1.16) per share for the quarter, up from their previous forecast of ($1.36). The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($4.55) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ FY2024 earnings at ($3.97) EPS and FY2025 earnings at ($1.85) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.06. The firm had revenue of $13.08 million for the quarter, compared to the consensus estimate of $4.63 million. During the same quarter in the prior year, the firm earned ($0.49) earnings per share.

Several other research firms have also weighed in on TARS. Barclays upped their price objective on Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. Lifesci Capital reaffirmed an “outperform” rating on shares of Tarsus Pharmaceuticals in a report on Tuesday, December 26th. The Goldman Sachs Group upped their price objective on Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the stock a “neutral” rating in a report on Thursday, February 29th. Oppenheimer reaffirmed an “outperform” rating and set a $59.00 price objective (up previously from $55.00) on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 28th. Finally, Jefferies Financial Group increased their price target on Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $48.38.

Tarsus Pharmaceuticals Stock Down 4.6 %

TARS stock opened at $32.85 on Friday. Tarsus Pharmaceuticals has a 1-year low of $12.57 and a 1-year high of $40.40. The business’s 50 day moving average is $33.81 and its 200-day moving average is $24.22. The company has a current ratio of 6.93, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 4,436 shares of the stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $135,741.60. Following the transaction, the general counsel now directly owns 40,951 shares of the company’s stock, valued at approximately $1,253,100.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, General Counsel Bryan Wahl sold 4,436 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $135,741.60. Following the sale, the general counsel now owns 40,951 shares in the company, valued at approximately $1,253,100.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bobak R. Azamian sold 10,415 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $30.60, for a total transaction of $318,699.00. Following the sale, the chief executive officer now owns 26,456 shares in the company, valued at approximately $809,553.60. The disclosure for this sale can be found here. Insiders have sold a total of 24,496 shares of company stock valued at $749,578 in the last three months. 11.54% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in TARS. Royal Bank of Canada lifted its stake in Tarsus Pharmaceuticals by 122.0% in the 2nd quarter. Royal Bank of Canada now owns 2,817 shares of the company’s stock valued at $50,000 after purchasing an additional 1,548 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Tarsus Pharmaceuticals by 310.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,736 shares of the company’s stock valued at $66,000 after purchasing an additional 2,825 shares during the last quarter. UBS Group AG raised its stake in shares of Tarsus Pharmaceuticals by 37.0% during the first quarter. UBS Group AG now owns 4,226 shares of the company’s stock valued at $71,000 after acquiring an additional 1,142 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Tarsus Pharmaceuticals by 362.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,832 shares of the company’s stock valued at $78,000 after acquiring an additional 3,004 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Tarsus Pharmaceuticals by 22.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,560 shares of the company’s stock valued at $92,000 after acquiring an additional 824 shares during the last quarter. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.